Theratome Bio Invested 2016

Theratome Bio is developing a portfolio of therapeutics derived from the secretome of adult stem cells for conventional therapy options. Its lead product Thera-101 is an injectable biologic drug designed to be first-line therapy for ischemic brain injury, including stroke. First-in-human clinical trial of Thera-101 is in progress. www.theratomebio.com


Looking for Funding?

VisionTech Partners may be able to help. Through VisionTech Angels and a broad network of investors and business resources, our goal is to help promising ventures succeed. We focus on early stage and early growth technology-based companies in Indiana and the Midwest.

If you have questions or would like more information, Contact Us. If you’re ready to start the process, Submit Your Business Plan using the secure website of Gust, the global platform for angel investing. We look forward to hearing from you!